Rita C. Peters

Climbing out of a reputation hole can start with adopting a quality culture.

While overall industry performance is trending positive, quality failures continue to negatively impact patients and the bio/pharma industry.

The editors welcome technical article contributions from biopharma industry experts.

Half a century after man first walked on the moon, space-based science is exploring benefits for Planet Earth.

FDA and USP take sides in debate on biologic drug standards.

FDA’s annual manufacturing report card shows more quality compliance is needed.

Pharma delivers a positive message with renewed efforts to eradicate malaria.

Promoting patient compliance with drug regimens extends beyond the formulation laboratory.

Do patients get what they pay for when they demand cheaper drugs?

Biosimilars, pricing strategies, and technology investments will influence growth in spending on drugs.